Also found in: Encyclopedia.
ARQAutomatic Repeat-reQuest
ARQArquitecto (Portuguese)
ARQArquitecto (Spanish)
ARQAdmission Request
ARQAutomatic Request
ARQAsking the Right Questions
ARQAutomatic Request for Repetition
ARQAutomatic Repeat Queuing
ARQAutomatic Retransmission on Request
ARQAutomated Response to Query
ARQAnnual Review Questionnaire
ARQAviation Readiness Qualification
ARQAutomatic Retransmission Queue
ARQAuto Rate Quote (insurance)
ARQAutomatic Repeat Request/Query
ARQAddress Resolution Query
ARQAutomated Request to Query
References in periodicals archive ?
ARQ managing director Graham Dorward said: "Our aim is to reduce energy consumption and CO2 emissions.
marking the initiation of a Phase 1, dose escalation trial in Japan with ARQ 197, a small molecule, selective inhibitor of the c-Met receptor tyrosine kinase.
Upon commercialization, ArQule will receive double-digit royalties from Kyowa on net sales of ARQ 197.
In a previous report, we demonstrated that BSE experimentally passaged in homozygous ARQ sheep showed enhanced infectivity (compared with cattle BSE) as determined in transgenic mice expressing bovine PrP protein (24).
The phase III trial is a randomised, double-blinded, controlled study of previously treated patients with locally advanced or metastatic, non-squamous NSCLC who will receive ARQ 197 plus erlotinib or placebo plus erlotinib.
C]-encoding ARR haplotype only are resistant to natural TSE infections, whereas those carrying the homozygous VRQ or ARQ haplotypes are highly susceptible.
ARQ 650RP is ArQule's second major platform for oncology drug discovery, distinct from the Company's E2F platform, which is partnered with Roche and includes a lead compound under investigation in several clinical trials and a second-generation compound in late pre-clinical development.
TSE 4568) today announced the presentation of data from a Phase 2 clinical trial at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) showing encouraging overall survival (OS) results with ARQ 197 in combination with erlotinib among patients with advanced, refractory non-small cell lung cancer.
presented interim results for the ongoing phase 1 monotherapy trial of ARQ 501 at the annual meeting of the American Society of Clinical Oncology ("ASCO").
Product Development Agreement Focused on ARQ 197, c-Met Inhibitor, With Discovery Collaboration Directed Toward Novel Kinase Inhibitors
today announced that it had successfully enrolled its first patient in a Phase 1b/2 combination trial of ARQ 501 and gemcitabine.
Nasdaq: ARQL) today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 087, an orally bioavailable, potent multi-kinase inhibitor with pan-FGFR (fibroblast growth factor receptor) activity.